EMD for Treatment of Proximal Class-II Furcation Involvements (NCT03320135) | Clinical Trial Compass
CompletedNot Applicable
EMD for Treatment of Proximal Class-II Furcation Involvements
Brazil34 participantsStarted 2017-10-20
Plain-language summary
The aim of the present study is to evaluate the clinical response of proximal furcations treated with enamel matrix derivative proteins (EMD).
Who can participate
Age range18 Years – 35 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of generalized aggressive periodontitis (Armitage, 1999; American Academy of Periodontology, 2015);
* Have undergone a first approach for periodontal treatment (full-mouth ultrasonic debridement);
* Presence of one proximal class-II furcation presenting probing depth \> 4 mm and bleeding on probing ;
* Good general health;
* Agree to participate in the study and sign the informed consent form (TCLE) after explaining the risks and benefits;
Exclusion Criteria:
* Systemic problems (cardiovascular alterations, blood dyscrasias, immunodeficiency - ASA III / IV / V) that contraindicate the periodontal procedure;
* Have used antibiotics and anti-inflammatories in the last six months;
* Smoke ≥ 10 cigarettes/day;
* Pregnant or lactating;
* Chronic use of medications that may alter the response of periodontal tissues;
* Indication of antibiotic prophylaxis for dental procedures;
What they're measuring
1
Horizontal clinical attachment level
Timeframe: 1 year
Trial details
NCT IDNCT03320135
SponsorUniversidade Estadual Paulista Júlio de Mesquita Filho